China SXT Pharmaceuticals-ASXTC
13F holders, Q4 2025 (December 31)8holders −2
2new positions
4sold out
1famous investor
$1.60avg. 13F price*
At the end of Q4 2025, 8 institutions reported holding China SXT Pharmaceuticals-A (SXTC) in their 13F filings, down 2 from Q3 2025. 2 opened new positions and 4 sold out. The largest holders were Citadel Advisors ($241K), Invesco Ltd. ($137K) and Geode Capital Management, LLC ($86K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- China SXT Pharmaceuticals-A
- CUSIP
- G2161P157
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $37K |
| Exits | 4 | $136K |
All 13F filers, Q3 2025 → Q4 2025: 125,531 shares bought and 108,795 shares sold, net +16,736 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Citadel Advisors | 0.00% | Add +208.8% | 150,576 | $241K |
| Invesco Ltd. | 0.00% | Reduce -4.8% | 85,331 | $137K |
| Geode Capital Management, LLC | 0.00% | No change | 53,671 | $86K |
| XTX Topco Ltd | 0.00% | New | 22,774 | $36K |
| Virtu Financial LLC | 0.00% | Reduce -57.4% | 12,355 | $20K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -36.5% | 1,827 | $3K |
| Royal Bank of Canada | 0.00% | New | 818 | $1K |
| UBS Group AG | 0.00% | Add +122.0% | 222 | $356 |
"% of holder's portfolio" is SXTC's weight in each manager's 13F, not the share of China SXT Pharmaceuticals-A the manager owns.